MEmbranous Nephropathy Trial Of Rituximab (MENTOR)

Sponsors and Collaborators
Mayo Clinic

Contact
Fernando C Fervenza, M.D., Ph.D.
507-266-7083
fervenza.fernando@mayo.edu

Lori A Riess
507-266-1047
riess.lori@mayo.edu

Eligibility

  • Age >18 years
  • Proteinuria > 5g/24h despite ACEi and/or ARB treatment for > 3 months
  • Estimated or quantified  GFR > 40 ml/min/1.73m2 while taking ACEi/ARB therapy
  • Resistant to cyclosporine (CSA) are excluded but patients who initially responded to CSA but relapsed off CSA are eligible for the study

Principal Investigator
Fernando C. Fervenza, M.D., Ph.D., Mayo Clinic

ClinicalTrials.gov Identifier
NCT01180036

Loading links....
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters